News and analysis of Biotech stocks. No buy or sell recommendations.

Visit SeekingAlpha Biotech Stocks

Sequenom Down on Threat of Competition

Posted on October 07, 2008

Typical of the irony in this market, after buying a large swath of Sequenom (SQNM) Monday at $21, in after hours comes news of competition (i.e. a study of 18 patients). Details found here.Researchers led by Stephen Quake of Stanford University in California created a way to look for the extra chromosomes that cause Down's and similar birth detects in the tiny amounts of fetal DNA that circulate in the mother's blood.Quake's team demonstrated the accuracy of the new genetic test in a small study involving 18 women.Quake said the new test could be widely available in two or three years, and ...

Original article link


genetic , health